相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future
Alexey V. Danilov
CLINICAL THERAPEUTICS (2013)
Waldenstrom's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features
Steven P. Treon
HEMATOLOGICAL ONCOLOGY (2013)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase
Laurence Elias et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Activity of BTK and HDAC inhibitors alone and in combination in a mouse model of non-small cell lung cancer
Corrinne G. Lobe et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Molecular pathogenesis of chronic lymphocytic leukemia
Gianluca Gaidano et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Current Status of Targeted Therapies for Mantle Cell Lymphoma
Julie E. Chang et al.
DRUGS (2011)
New drugs for aggressive B-cell and T-cell lymphomas
Niels Murawski et al.
LANCET ONCOLOGY (2010)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
分享论文
